{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-024273","form_type":"8-K","ticker":"ZVSA","cik":"0001859007","company_name":"ZyVersa Therapeutics, Inc.","filed_at":"2025-11-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.847510+00:00","generated_at":"2026-05-16T18:32:33.801822+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"ZyVersa reports Q3 net loss of $19.8M; cash only $0.5M, going concern risk","bullets":["Cash on hand $0.5M as of Sept 30, 2025; expects month-to-month liquidity only, needs additional financing.","Net loss $19.8M vs $2.4M in Q3 2024, driven by $18.6M impairment of in-process R&D due to market cap decline.","Pre-tax loss $20.7M; R&D expense $0.4M (-16.3% YoY), G&A $1.7M (-5.1% YoY).","Raised $2.05M in Q3 2025, $4.05M YTD; company flags need for equity/debt or collaboration funding.","Lead programs: VAR 200 for FSGS (kidney) and IC 100 for cardiometabolic diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-024273","json":"https://secwatch.observer/filing/0001493152-25-024273.json","markdown":"https://secwatch.observer/filing/0001493152-25-024273.md","text":"https://secwatch.observer/filing/0001493152-25-024273.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1859007/000149315225024273/0001493152-25-024273-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1859007/000149315225024273/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T18:32:33.801822+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}